CTRI

Alternative Hypothesis

(H1) Shamana Snehapana is more effective than Virechana Karma in the management of dyslipidemia

(H2) Virechana Karma is more effective than Shamana Snehapana in the management of dyslipidemia

AIM:

To evaluate and compare the efficacy of Shamana Snehapana and Virechana Karma in the management of Dyslipidemia

OBJECTIVES

To study the complete etiopathology, symptomatology and progress of Dyslipidemia According to Ayurveda as well as modern science

To study the efficacy of Shamana Snehapana in the management of dyslipidemia

To study the efficacy of Virechan in the management of dyslipidemia

To study Virechan karma according to all Ayurvedic texts

OBJECTIVE CRITERIA

LIPID PROFILE

TOTAL CHOLESTEROL more than 200 mgdL

LDL more than100 mgdl

TRIGLYCERIDES more than150 mgdL

HDL less than 40 mgdL

APOLIPOPROTEIN B more than 120mgdL

SUBJECTIVE CRITERIA

There are no signs and symptoms of dyslipidemia

Inclusion criteria

1Age between 18 to 60 yrs

2 On the basis of National Cholesterol Education Program (NCEP) Adult Treatment Plan(ATP) III

Guidelines patients having

TOTAL CHOLESTEROL more than 200 mgdL

LDL more than 100 mgdL

TRIGLYCERIDES more than 150 mgDl

HDL less than 40 mgDl

APOLIPOPROTEIN B more than 120mgdL

Patients who are Snehapana Yogya

Patients who are Virechana Yogya

Exclusion criteria

Age below 18 years and more than 60 years

Patients with uncontrolled HTN uncontrolled DM

Pregnant / lactating women

Virechan Ayogya

Snehpana Ayogya

Heart Diseases, Kidney Diseases Stroke Liver Disease

Pulmonary Dysfunction or COPD

Patients with a history of any acute or chronic infectious diseases like TB AIDS and Other STDs

Patients taking medications like corticosteroids hormonal therapy

antidepressants or any other drugs which may affect the outcome of the

study

Investigations

Following investigations will be carried out before and after treatment

LIPID PROFILE

APOLIPOPROTEIN B

To rule out other pathologies CBC and Urine (R and M) will be done

Study Design

Study type: Intervention

Purpose: Treatment

Masking: Open labelled. no masking

Study design: Randomized clinical trial

Allocation: Computer generated randomization

Timing: Prospective

End point: Efficacy and safety

No. of Groups: 2

Sample size: 30 patients (15 patients in each group)

Details of interventions

GROUPING: Selected patients will be divided randomly into two group

GROUP A

15 patients will be treated with Shamana Snehapana

GROUP B

15 patients will be treated with Virechana Karma

GROUP A: SHAMAN SNEHAPANA WITH TRIPHALADI TAIL

DRUG	DOSE & ANUPANA	ADMINISTRATION TIME	DURATION
Triphala Trikatu and Saindhava Siddha Taila	30-50ml With Mudga Yusha	Annakala Prakankshit	28 Days

GROUP B: VIRECHANA KARMA

Procedure is divided into 3 parts as follows

PURVAKARMA

PROCEDURE	DRUG AND DOSE	DURATION
Deepana and Pachana	Drug Trikatu Churna Dose 4 to 6 gm per day (2 to 3gm twice a day per Aatura Agni) Time of Administration Before Food Anupana Ushna Jala Route Oral Route	3 to 5 Days (Till the Karma appearance of Samyak Deepana and Pachana Lakshana observed)
Snehapana	Drug Tila taila 3 to 7 Days Dose 20 to 40 ml starting dose in vardhamana Krama (as per Aatura-Kostha and Agni) Time of Administration EarlyMorning at empty stomach Anupana Ushna Jala Route Oral Route Diet Light Diet (drava ushna annabhishyan natisnidgha asankirn a)	3 to 7 Days
Sarvanga Abhyanga and baspa sweden	Drug Tila taila QS (Approx 50 ml) For 1st 2nd 3rd day during vishrama kala after completionof abhyantar snehapana and also 4th day prior to Virechan karma	4days